Most Read Articles
3 days ago
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.

Novel chimeric monoclonal antibody offers hope in refractory colorectal cancer

01 Aug 2020

Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.

The study included 63 patients with advanced, refractory cancer who expressed MUC5AC antigen in tumour tissue (median age, 58 years; 54 percent male). The mean time from initial diagnosis to study entry was 3.79 years, and all patients had undergone a median of three prior cancer-directed therapies.

All patients received infusions of ensituximab at 3 mg/kg every 2 weeks. Among 57 patients (90 percent) who were evaluable, the median overall survival (OS) was 6.8 months and longer than the 5.0 months observed in the historical control (p=0.007). Twelve patients (21 percent) achieved stable disease (SD) at the end of the first treatment course. Forty-nine patients were evaluable for progression-free survival, which had a mean duration of 70.4 days.

The study drug was well tolerated. Commonly reported treatment-related adverse events (AEs) were fatigue (38 percent), anaemia (30 percent), nausea (15 percent), vomiting (11 percent), increased bilirubin (9 percent), constipation (8 percent), decreased appetite (6 percent), and diarrhoea (6 percent).

Serious AEs potentially related to ensituximab occurred in four patients and included anaemia, nausea, increased bilirubin, and hypoxia. None of the patients discontinued treatment due to drug-related AEs.

The present data provide supporting rationale for investigating combination therapies containing ensituximab plus interleukin-15 or other agents, such as chemotherapy, to boost efficacy in the patient population, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Pank Jit Sin, 14 Apr 2020
With the movement control order (MCO) in full gear, most conferences and meetings are being postponed or cancelled. Some have taken to having conferences and meetings in a virtual setting, such as the recently ended American College of Cardiology/World Congress of Cardiology (ACC.20/WCC) conference. MIMS and the Asian Young Pharmacist Group (AYPG) took this opportunity to engage with pharmacists in the form of a Zoom meeting. 
Pearl Toh, 05 Aug 2020
The direct oral anticoagulant apixaban may help prevent deaths when given at prophylactic or therapeutic doses in hospitalized COVID-19 patients with elevated D-dimer levels, according to an analysis presented during the ISTH 2020 Congress.